OM
IMNM icon

Opaleye Management’s Immunome IMNM Stock Holding History

Opaleye Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,185,000
Closed -$37.3M – 58
2025
Q3 		$37.3M Sell
3,185,000
-344,581
-10% -$3.43M 5.27% 5
2025
Q2 		$32.8M Sell
3,529,581
-20,419
-0.6% -$167K 6.64% 3
2025
Q1 		$23.9M Buy
3,550,000
+1,510,000
+74% +$14.5M 5.32% 7
2024
Q4 		$21.7M Buy
2,040,000
+802,500
+65% +$9.7M 3.79% 8
2024
Q3 		$18.1M Buy
1,237,500
+135,000
+12% +$1.92M 3.02% 8
2024
Q2 		$13.3M Buy
+1,102,500
New +$17.2M 3.05% 7

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Opaleye Management's IMNM Position: Q4 2025 in Review

Opaleye Management sold out of Immunome (IMNM) in Q4 2025, closing a stake of 3,185,000 shares — an estimated $37.3M sold.

Opaleye Management first reported a position in IMNM in Q2 2024 and held it in 6 quarters. The position peaked at $37.3M in Q3 2025. 182 funds tracked by Wall St. Rank hold IMNM as of Q4 2025.

  • Opaleye Management reported no remaining Immunome position as of Q4 2025 after selling out during the quarter.
  • Opaleye Management sold 3,185,000 Immunome shares in Q4 2025, an estimated $37.3M.
  • Opaleye Management first reported a position in Immunome in Q2 2024 and held it in 6 quarters.
  • Opaleye Management's Immunome position peaked at $37.3M in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Immunome as of Q4 2025.

Based on Opaleye Management's 13F filing for Q4 2025, filed 17 Feb 2026.